1-7 of 7
S. John Weroha
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

Open Access
Eleftheria Kalogera, Wendy K. Nevala, Heidi D. Finnes, Vera J. Suman, Jill M. Schimke, Carrie A. Strand, Lisa A. Kottschade, Rachel A. Kudgus, Sarah A. Buhrow, Laura R. Becher, Liyi Geng, Gretchen E. Glaser, Megan E. Grudem, Aminah Jatoi, Carolyn M. Klampe, Amanika Kumar, Carrie L. Langstraat, Robert R. McWilliams, Andrea E. Wahner Hendrickson, S. John Weroha, Yiyi Yan, Joel M. Reid, Svetomir N. Markovic, Matthew S. Block
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (12): 2623–2635.
https://doi.org/10.1158/1078-0432.CCR-23-3196
Published: 14 June 2024
View articletitled, A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
Open the PDF for A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Abstract PR02: Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers

Free
Jacob J. Kennedy, Shrabanti Chowdhury, Sara R. Savage, Xiaonan Hou, Catherine J. Huntoon, Richard G. Ivey, Qing Yu, Chenwei Lin, Dongqing Huang, Lei Zhao, Uliana J. Voytovich, Regine M. Schoenherr, Zahra Shire, Steven J. Skates, Jeffrey R. Whiteaker, Andrew N. Hoofnagle, Samuel C. Mok, Bing Zhang, Larry M. Karnitz, S. John Weroha, Steven P. Gygi, Scott H. Kaufmann, Pei Wang, Michael J. Birrer, Amanda G. Paulovich
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): PR02.
https://doi.org/10.1158/1557-3265.OVCA19-PR02
Published: 01 July 2020
View articletitled, Abstract PR02: Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers
Journal Articles

The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer

Available to Purchase
Artur A. Serebrenik, Prokopios P. Argyris, Matthew C. Jarvis, William L. Brown, Martina Bazzaro, Rachel I. Vogel, Britt K. Erickson, Sun-Hee Lee, Krista M. Goergen, Matthew J. Maurer, Ethan P. Heinzen, Ann L. Oberg, Yajue Huang, Xiaonan Hou, S. John Weroha, Scott H. Kaufmann, Reuben S. Harris
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3397–3407.
https://doi.org/10.1158/1078-0432.CCR-19-2786
Published: 01 July 2020
View articletitled, The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer
Open the PDF for The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract IA11: Ovatars in preclinical drug development and clinical trial for ovarian cancer patients

Free
S. John Weroha
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): IA11.
https://doi.org/10.1158/1557-3265.PDX16-IA11
Published: 15 August 2016
View articletitled, Abstract IA11: Ovatars in preclinical drug development and clinical trial for ovarian cancer patients
Journal Articles

Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer

Free
Mariam Al Hilli, S. John Weroha, Marc Becker, Xiaonan Hou, Sean Harrington, Sarah McKinstrey, Kimberly Kalli, Karin Goodman, Keith Wilcoxen, Elizabeth Swisher, Scott Kaufmann, Paul Haluska
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): PR05.
https://doi.org/10.1158/1078-0432.OVCA13-PR05
Published: 13 May 2014
View articletitled, Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer
Journal Articles

Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

Free
S. John Weroha, Marc A. Becker, Sergio Enderica-Gonzalez, Sean C. Harrington, Ann L. Oberg, Matthew J. Maurer, Sarah E. Perkins, Mariam AlHilli, Kristina A. Butler, Sarah McKinstry, Stephanie Fink, Robert B. Jenkins, Xiaonan Hou, Kimberly R. Kalli, Karin M. Goodman, Jann N. Sarkaria, Beth Y. Karlan, Amanika Kumar, Scott H. Kaufmann, Lynn C. Hartmann, Paul Haluska
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (5): 1288–1297.
https://doi.org/10.1158/1078-0432.CCR-13-2611
Published: 02 March 2014
View articletitled, Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
Open the PDF for Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors

Available to Purchase
Marc A. Becker, Xiaonan Hou, Sean C. Harrington, S. John Weroha, Sergio E. Gonzalez, Kristina A. Jacob, Joan M. Carboni, Marco M. Gottardis, Paul Haluska
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1808–1817.
https://doi.org/10.1158/1078-0432.CCR-11-1806
Published: 14 March 2012
View articletitled, IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors
Open the PDF for IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors in another window
Includes: Supplementary data